StockNews.AI
EVGN
StockNews.AI
180 days

Evogene Schedules Fourth Quarter 2024 Financial Results Release

1. Evogene to release Q4 2024 financial results on March 6, 2025. 2. Conference call set at 9:00 AM ET; pre-registration required. 3. Event may clarify EVGN's strategic advancements in computational biology. 4. Announcement reiterates focus on advanced tech engines for product discovery.

Earnings
-4.1%Current Return
VS
-1.81%S&P 500
$1.46502/20 07:21 AM EDTEvent Start
$1.40502/21 01:57 PM EDTLatest Updated
5m saved
Insight
Article

FAQ

Why Neutral?

This scheduled earnings announcement is a routine event that could cause short-term volatility if results differ from expectations; historically, such releases show modest impact unless surprises emerge.

How important is it?

While financial results are important, the announcement itself is anticipated and likely already factored into the stock price.

Why Short Term?

Earnings reports typically influence near-term trading as investors adjust positions based on final numbers.

Related Companies

EVGN
Zoom conference call scheduled for March 6, 2025, 9:00 AM ET , /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science product discovery and development, announced today that it will release its financial results for the fourth quarter of 2024, on Thursday, March 6, 2025. Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time). To join the conference, please register in advance: https://us06web.zoom.us/webinar/register/WN_1cToyoipTfW8X0xtgEqPfw The entire conference will be available online on the company's website a few days after. About Evogene: Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science-based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost. Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its four subsidiaries including: Biomica Ltd. (www.biomicamed.com) - developing and advancing novel microbiome-based therapeutics to treat human disorders powered by MicroBoost AI; Lavie Bio Ltd. (www.lavie-bio.com) - developing and commercially advancing, microbiome-based ag-biologicals powered by MicroBoost AI; AgPlenus Ltd. (www.agplenus.com) - developing next-generation ag chemicals for effective and sustainable crop protection powered by ChemPass AI; Casterra Ag Ltd. (www.casterra.co) - developing and marketing superior castor seed varieties producing high yield and high-grade oil content on an industrial scale for the biofuel and other industries powered by GeneRator AI. For more information, please visit: www.evogene.com. Contact [email protected]Tel: +972-8-9311901 Logo - https://mma.prnewswire.com/media/1947468/4576969/Evogene_Logo.jpg SOURCE Evogene WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News